Drugs that contain Lifitegrast

1. Drug name - XIIDRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7745460 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(2 years from now)

US7928122 NOVARTIS Modulators of cellular adhesion
Nov, 2024

(2 years from now)

US7314938 NOVARTIS Modulators of cellular adhesion
Mar, 2025

(2 years from now)

US8084047 NOVARTIS Compositions and methods for treatment of eye disorders
May, 2026

(3 years from now)

US9890141 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof
Oct, 2030

(8 years from now)

CN105820160A NOVARTIS Cell Adhesion Regulator
Nov, 2024

(2 years from now)

CN1902195B NOVARTIS Cell Adhesion Regulator
Nov, 2024

(2 years from now)

CN105820160B NOVARTIS Cell Adhesion Regulator
Nov, 2024

(2 years from now)

CN1902195A NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

CN101175488B NOVARTIS Compositions And Methods For Treating Eye Disease
May, 2026

(3 years from now)

CN101175488A NOVARTIS Composition And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

IN279168B NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN200601233P2 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN201003759P2 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN250181B NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN201100459P2 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN348854B NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

IN284595B NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

IN200708114P1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP1682537B1 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

EP1682537A1 NOVARTIS Modulators Of Cellular Adhesion
Nov, 2024

(2 years from now)

EP1881823A4 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP1881823A1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP2444079B1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP1881823B1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

EP2444079A1 NOVARTIS Compositions And Methods For Treatment Of Eye Disorders
May, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124000 NOVARTIS Modulators of cellular adhesion Nov, 2024

(2 years from now)

US7790743 NOVARTIS Modulators of cellular adhesion Nov, 2024

(2 years from now)

US9216174 NOVARTIS Modulators of cellular adhesion Nov, 2024

(2 years from now)

US8592450 NOVARTIS Compositions and methods for treatment of eye disorders May, 2026

(3 years from now)

US9447077 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof Apr, 2029

(6 years from now)

US8367701 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof Apr, 2029

(6 years from now)

US8168655 NOVARTIS Compositions and methods for treatment of eye disorders May, 2029

(6 years from now)

US9353088 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof Oct, 2030

(8 years from now)

US8927574 NOVARTIS Crystalline pharmaceutical and methods of preparation and use thereof Nov, 2030

(8 years from now)

US9085553 NOVARTIS LFA-1 inhibitor and methods of preparation and polymorph thereof Jul, 2033

(10 years from now)

US11058677 NOVARTIS LFA-1 inhibitor formulations Dec, 2033

(11 years from now)

Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
5% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.